Actively Recruiting
Evaluating Rezpegaldesleukin Injection Versus Placebo in Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis in a Randomized, Double-Blind Study
Led by Nektar Therapeutics · Updated on 2026-09-08
510
Participants Needed
13
Research Sites
30 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of Rezpegaldesleukin in people aged 12 years and older who have moderate to severe atopic dermatitis. This Phase 3, randomized, double-blind study compares Rezpegaldesleukin to a placebo to assess its impact on skin symptoms and severity over approximately 15 months. The goal is to better understand how this treatment influences the condition in participants who have not responded well to topical therapies. Participants will receive Rezpegaldesleukin or a placebo by subcutaneous injection during an induction period every 2 weeks. This is followed by a maintenance period with Rezpegaldesleukin given either every 4 or 12 weeks or placebo every 4 weeks. There is also an open-label escape phase where dosing frequency of Rezpegaldesleukin is adjusted by the investigator. Treatments are administered under blinded conditions during the induction and maintenance phases. During the study, participants will have their skin condition evaluated through assessments like the Investigators Global Assessment IGA and Eczema Area and Severity Index EASI. Other measurements include itch and skin pain scales, sleep quality, and questionnaires related to asthma and sinus symptoms. Safety is monitored by tracking adverse events through about week 56 of participation. The overall study duration for each participant is about 15 months.
CONDITIONS
Brief Title
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Research Team
N
Nektar Recruitment
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here